HZ
Therapeutic Areas
HUTCHMED Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Fruquintinib (ELUNATE®) | Metastatic Colorectal Cancer (3L+) | Approved |
| Fruquintinib | Metastatic Colorectal Cancer (2L) | Phase 3 |
| Savolitinib (ORPATHYS®) | NSCLC with MET exon 14 skipping alterations | Approved |
| Savolitinib | Papillary Renal Cell Carcinoma | Phase 3 |
| Surufatinib (SULANDA®) | Advanced Neuroendocrine Tumors (pan-NET, epNET) | Approved |
| Surufatinib | Biliary Tract Cancer, Osteosarcoma, Thyroid Cancer | Phase 2/3 |
| HMPL-306 | IDH1/2 Double Mutant Hematological & Solid Tumors | Phase 1 |
| HMPL-760 | B-cell Malignancies | Phase 1 |
Leadership Team at HUTCHMED
ST
Simon To
Chairman of the Board
WS
Weiguo Su
Chief Executive Officer & Chief Scientific Officer
JC
Johnny Cheng
Chief Financial Officer
MS
Michael Shi
Chief Medical Officer & Head of Global Development
SD
Samantha Du
Founder and Non-Executive Director
KA
Karen Atkin
Non-Executive Director, Chair of Audit Committee
DE
Dan Eldar
Senior Vice President, Business Development
LZ
Li Zheng
Senior Vice President, Translational Medicine
YW
Yizhe Wang
Senior Vice President, General Counsel & Company Secretary
MK
Marek Kania
Senior Vice President, Global Head of Medical Affairs